Skip navigation

Achieve ADF Labeling • Reduce Abuse Potential • Integrate Technologies to Support Deterrence

March 7-8, 2017
  • Alexandria, VA

CBI’s Abuse-Deterrent Formulations Summit provides clarity on the evolving regulatory expectations for both branded and generic opioid manufacturers to obtain an ADF label. Join us to explore best practices to reduce abuse potential through innovative study designs, technology utilization and the latest developments from CMS and Congress impacting access.

Transformative Thought Leadership on:

  • FDA coverage of “Final Guidance on General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products”
  • Processes for navigating intellectual property framework
  • Translate abuse deterrent (AD) data into AD label claims
  • Transformative technologies that protect against oral abuse
  • Breakthrough formulation technologies that target the source of abuse
  • Demonstrate correlations between in vitro results and in vivo performance of manipulated extended release abuse deterrence
  • Strategies for data interpretation and primary analysis of abuse potential

Previous Attendee Acclaim:

Great conference, very informative and multifaceted perspective on ADF, very impressed with Kyle’s attention to conference needs and making smooth transitions. Excellent source of current ADF considerations and technology from diverse perspectives.

Formulator, Lannett Company

The best CBI conference I’ve attended.

Vice President, Collegium Pharmaceuticals

It was a well organized conference that brings together KOLs and a broad audience. Valuable exchange is facilitated.

International Project Leader, Grünenthal

Enjoyed the conference and networking.

CSO, Camargo

March 7-8, 2017 Embassy Suites by Hilton Alexandria, VA

ADF 2017 — Abuse-Deterrent Formulations Summit

Achieve ADF Labeling • Reduce Abuse Potential • Integrate Technologies to Support Deterrence

CBI’s Abuse-Deterrent Formulations Summit provides clarity on the evolving regulatory expectations for both branded and generic opioid manufacturers to obtain an ADF label. Join us to explore best practices to reduce abuse potential through innovative study designs, technology utilization and the latest developments from CMS and Congress impacting access.

Transformative Thought Leadership on:

  • FDA coverage of “Final Guidance on General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products”
  • Processes for navigating intellectual property framework
  • Translate abuse deterrent (AD) data into AD label claims
  • Transformative technologies that protect against oral abuse
  • Breakthrough formulation technologies that target the source of abuse
  • Demonstrate correlations between in vitro results and in vivo performance of manipulated extended release abuse deterrence
  • Strategies for data interpretation and primary analysis of abuse potential

Previous Attendee Acclaim:

Great conference, very informative and multifaceted perspective on ADF, very impressed with Kyle’s attention to conference needs and making smooth transitions. Excellent source of current ADF considerations and technology from diverse perspectives.

Formulator, Lannett Company

The best CBI conference I’ve attended.

Vice President, Collegium Pharmaceuticals

It was a well organized conference that brings together KOLs and a broad audience. Valuable exchange is facilitated.

International Project Leader, Grünenthal

Enjoyed the conference and networking.

CSO, Camargo

March 7-8, 2017 Embassy Suites by Hilton Alexandria, VA